Showing 1011-1020 of 7672 results for "".
SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.SCALE 2024: Dr. Michelle Henry on Innovative Skincare Products and Lasers in Skin of Color
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michelle-henry-innovative-skincare-products-and-lasers-skin-color/26374/Michelle Henry, MD, discusses innovative skincare products and lasers in skin of color, including her top 10 tips for ensuring best outcomes and reducing adverse events, at Music City SCALE.Clinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts diDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiEndo’s Qwo for Treatment of Cellulite
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/endos-qwo-for-treatment-of-cellulite/23466/Launching soon, the first injectable to target cellulite performed well in clinical trials.Second Primary Tumors and Immune Checkpoint Inhibitors: What Do We Know?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/second-primary-tumors-and-immune-checkpoint-inhibitors-what-do-we-know/23452/New evidence reveals a potential link between ICI treatment and risk for secondary cancers.Power of the Group: Quality of Care in AD
https://practicaldermatology.com/topics/atopic-dermatitis/power-of-the-group-quality-of-care-in-ad/19880/When researchers undertook a survey of eczema centers worldwide, they uncovered common barriers to care and identified potential solutions. Eric Simpson, MD, MCR provides on overview of the Quality of Care in Atopic Dermatitis initiative, with an emphasis on the value of the group-based analysis ofCOVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditiDermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic derGolden Combinations
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/golden-combinations/19699/Aesthetic physicians are getting more comfortable using devices in combination. Michael H. Gold, MD discusses the rationale and some of his favorite combos.